Veeda Clinical Research buys European CRO Heads for an undisclosed sum

Veeda Clinical Research buys European CRO Heads for an undisclosed sum.

Expert Analysis:

• Veeda Acquires Heads: Veeda Clinical Research acquires Heads, a European CRO specializing in oncology trials, to strengthen its global market position.

• Global Expansion and Expertise: Veeda expands into major regions, gaining expertise in late-stage oncology trials, while Heads gains access to Indian and Southeast Asian markets.

• Heads' Global Presence and Expertise: Founded in 2010, Heads operates in 25 locations across Europe, North America, and Asia Pacific, adding oncology expertise to Veeda’s portfolio for comprehensive drug development services.

• Expanded Therapeutic Opportunities: Heads gain access to India’s diverse patient population for trials in oncology, diabetes, hypertension, and more, enhancing Veeda’s CRO services globally.

• CEO Statement on Acquisition: Mahesh Bhalgat, Group CEO of Veeda, States that the acquisition's role is enabling large-scale, multi-geography clinical trials and fostering innovative treatments.

• Binoy Gardi on Integration: Binoy Gardi, Executive Vice Chairperson of Veeda, states that the opportunity to expand markets, leverage complementary capabilities, and add value to clients during integration.